Orange stock, CAC 40 laggard, plunges more than 4%

Orange drops 4% and closes the line in a nearly stable CAC 40

Orange loses 4.13% to €14.40 at close, while the CAC 40 finishes the session with a gain of 0.2%. The performance gap is striking: the stock posts the strongest decline in the index, well ahead of other members in the red. Over the week, the loss reaches nearly 9%, bringing the monthly decline to -9.8%. The underlying momentum remains clearly unfavorable: since late August, the price had already broken through several successive support levels, and the quarterly decline now stands at -15.74%. Only the twelve-month performance remains positive, at +5%, but is eroding rapidly. Additionally, Orange Ventures announced on Tuesday a stake in Biolevate, a start-up specializing in process automation for life sciences, with no visible effect on today's quotation.

A triple moving average resistance 7 to 12% above the price, RSI approaching oversold territory

Orange's technical chart remains under heavy pressure. The price is now trading 7.13% below the 20-day moving average at €15.50, 10.14% below the 50-day moving average at €16.02, and 12.70% below the 200-day moving average at €16.49: the three moving averages form a thick technical resistance that distances the stock from any prospect of rapid recovery. The RSI at 37 is gradually approaching oversold territory, without crossing into it yet, reflecting persistent selling pressure without a clear signal of exhaustion at this time.

On fundamental grounds, when the company published its first-half 2026 results (July 28, 2026), the group raised its annual targets based on double-digit growth in Africa and the Middle East, while noting that net debt had risen to €35.7 billion, with a debt/EBITDAaL ratio of 2.4x following the MasOrange integration. These fundamental elements remain the main benchmarks available to assess the stock's trajectory, pending the next financial milestone.